drugset / Trial / NCT02570321

Cross-linking for Corneal Ulcers Treatment Trial

NCT02570321 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of this study is to determine if patients randomized to corneal collagen cross-linking plus medical therapy will have a lower prevalence of positive bacterial or fungal cultures immediately after the procedure than patients who received medical therapy alone. The secondary purpose of this study is to determine if patients randomized to corneal collagen cross-linking will have a better visual acuity at 3 and 12 months than patients who receive medical therapy alone.

Timeline

Start
2015-11
Primary completion
2018-06-18
Completion
2019-03-19

Outcome

Missed primary endpoint

paper 24-hour culture positivity, although this was not statistically significant (95% confidence interval [CI], 0.57-3.06; P = 0.51). PMID 31619359 ↗

paper There appears to be no benefit of adjuvant CXL in the primary treatment of moderate filamentous fungal ulcers PMID 31619359 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Amphotericin B Unknown 0.15 % Topical
Subject Natamycin Small molecule 5 % Topical

Indications